Summary
This Phase III trial evaluated tasimelteon (HETLIOZ®) for treating Jet Lag Disorder simulating an 8-hour eastward phase advance, the most challenging direction of travel for circadian adaptation. Results support tasimelteon as a pharmacological aid for travelers needing rapid circadian re-entrainment, with implications for complementary use alongside strategic light exposure protocols.
Key Findings
- Multicenter, randomized, double-blind, placebo-controlled design simulating an 8-hour phase advance (eastward travel scenario)
- Tasimelteon (a melatonin receptor agonist) was significantly more effective than placebo in reducing jet lag disorder symptoms
- Specific effect sizes and p-values not available from abstract alone, but trial met primary endpoints for sleep and daytime function outcomes
Categories
Sleep & Circadian Health: Tasimelteon targets melatonin receptors to re-entrain circadian rhythms, directly addressing jet lag disorder caused by rapid phase shifts across time zones.
Author(s)
CM Polymeropoulos, MA Mohrman, MS Keefe
Publication Year
2020
Related Publications
Sleep & Circadian Health
- Phototransduction by retinal ganglion cells that set the circadian clock
- The mammalian circadian timing system: organization and coordination of central and peripheral clocks
- The two‐process model of sleep regulation: a reappraisal
- Melanopsin is required for non-image-forming photic responses in blind mice
- Strange vision: ganglion cells as circadian photoreceptors